Dr. Iacono recently joined the University of Maryland faculty from University of Pittsburgh School of Medicine where he served as Medical Director of Lung Transplantation. Dr. Iacono has established a national reputation as an outstanding transplant pulmonologist and a translational investigator focusing on novel anti-rejection therapy. He has been a leader in developing aerosolized antirejection therapy to reduce the incidence of chronic lung transplant rejection and minimize systemic side effects of antirejection medications.
- Complications of lung transplantiation
- Markers of lung transplant rejection
- Novel anti-rejection therapies
- Aerosolized anti-rejection therapy for lung transplant patients
Patents, Inventions, Copyrights:
US patent application, November 11,1999: A32130-072396.0162 by Iacono et.al: “Uses of aerosol cyclosporine for prevention and treatment of pulmonary disease”
Medical Nebulizer dose concentrator filed by Drs. Iacono and Corcoran. December 1, 2000.
Iacono AT, Corcoran TE, Griffith BP, Grgurich WF, Smith DA, Zeevi A, Smaldone GC, McCurry KR, Johnson BA, Dauber JH. Aerosol Cyclosporine Therapy in Lung Transplant Recipients with Bronchiolitis Obliterans. Eur Respir J. 2004 Mar;23(3):384-90.
Burns KE, Iacono AT. Pulmonary Embolism on Postmortem Examination: An Under-Recognized Complication in Lung-Transplant Recipients? Transplantation 2004 Mar 15;77(5):692-8.
Corcoran TE, Smaldone GC, Dauber JH, Smith DA, McCurry KR, Burckart GJ, Zeevi A, Griffith BP, Iacono AT. Preservation of Post Transplant Lung Function with Aerosol Cyclosporine. Eur Respir J. 2004 Mar;23(3):378-83.
Donnenberg VS, Burckart GJ, Zeevi A, Griffith BP, Iacono AT, McCurry KR, Wilson JW, Donnenberg AD. P-glycoprotine Activity is Deceased in CD4+ but Not CD8+ Lung Allograft-Infiltrating T Cells During Acute Cellular Rejection. Transplantation 2004 Jun 15;77(11):1699-706.
Miller GG, Destarac L, Zeevi A, Girnita A, McCurry K, Iacono A, Murray JJ. Crowe D, Johnson JE. Ninan M, Milstone AP. Acute Humoral Rejection of Human Lung Allografts and Elevation of C4din Bronchoalveolar Lavage Fluid. Am J Transplant. 2004 Aug;4(8):1323-30.
Girnita AL, McCurry KR, Iacono AT , Duquesnoy R, Awad M, Spichty KJ, Yousem SA, Burckart G, Dauber JH, Griffith BP, Zeevi A. HLA-Specific Antibodies are Associated with High Grade and Persistent-Recurrent Lung Allograft Acute Rejection. J Heart Lung Transplant. 2004 Oct;23(10):1135-41.
DeVito Dabbs A, Hoffman LA, Swigart V, Happ MB, Iacono AT, Dauber JH. Using Conceptual Triangulation to Develop an Integrated Model fo the Symptom Experience of Acute Rejection after Lung Transplantation. Advances in Nursing Science 2004:26(4).
Smith-Seiller D, Iacono AT. Bronchiolitis Obliterans in the Lung Transplant Recipient. Advance for Nurse Practitioners 2004:11(4).
Donnenberg VS, Wilson JW, Burckart GJ, Zeevi a, Iacono A, Donnenberg AD. Measurement of Basal, Substrate Induced and Total P-Glycoprotein Activity in Bronchoalveolar Lavage T-Cell Subsets. Cytometry Part A 57A:75-85 (2004).
Dabbs Ade V, Hoffman LA, Swigart V, Happ MB, Dauber JH, McCurry KR, Iacono A. Striving for normalcy: symptoms and the threat of rejection after lung transplantation. Soc Sci Med. 2004 Oct;59(7):1473-84.
Zheng H, Schuetz E, Zeevi A, Zhang J, McCurry K, Webber S, Iacono A, Lamba J, Burckart GJ. Sequential analysis of tacrolimus dosing in adult lung transplant patients with MDR1 haplotypes. Journal of Clinical Pharmacology 2005; 45: 404-410.
De Vito Dabbs A, Hoffman LA, Iacono AT, Zullo TG, McCurry KR, Dauber JH. Are symptom reports useful for differentiating between acute rejection and pulmonary infection after lung transplantation? Heart Lung. 2004 Nov-Dec;33(6):372-80.
Girnita AL, Duquesnoy R, Yousem SA, Iacono AT, Corcoran TE, Buzoianu M, Johnson B, Spichty KJ, Dauber JH, Burckart G, Griffith BP, McCurry KR, Zeevi A. HLA-specific antibodies are risk factors for lymphocytic bronchiolitis and chronic lung allograft dysfunction. Am J Transplant. 2005 Jan;5(1):131-8.
De Vito Dabbs A, Kim Y, Vensak J, Studer S, Iacono A. Validation and refinement of the Questionnaire for Lung Transplant Patients. Prog Transplant. 2004 Dec;14(4):338-45.
Iacono AT, Johnson BA, Grgurich WF, Youssef JG, Corcoran TE, Seiler DA, Dauber JH, Smaldone GC, Zeevi A, Yousem SA, Fung JJ, Burckart GJ, McCurry KR, Griffith BP. A randomized trial of inhaled cyclosporine in lung-transplant recipients. N Engl J Med. 2006 Jan 12;354(2):141-50.
McCurry KR, Iacono A, Zeevi A, Yousem S, Girnita A, Husain S, Zaldonis D, Johnson B, Hattler BG, Starzl TE. Early outcomes in human lung transplantation with Thymoglobulin or Campath-1H for recipient pretreatment followed by posttransplant tacrolimus near-monotherapy. J Thorac Cardiovasc Surg. 2005 Aug;130(2):528-37.
Zeevi A, Spichty K, Banas R, Morel P, Iacono A, Dauber J, Yousem S, Pham S, Keenan R, Duquesnoy R, Griffith B. Two Types of CMV-Specific Memory Responses in Lung Transplant Recipients. Transplantation Proceedings 1999; 31(1-2):173-174.
Wang J, Zeevi A, McCurry K, Schuetz E, Zheng H, Iacono A, McDade K, Zaldonis D, Webber S, Watanabe R, Burckart G. Impact of ABCB1 (MDR1) haplotypes on tacrolimus dosing in adult lung transplant patients who are CYP3A5 3/3 nonexpressors. Transplant Immunology 15 (2006) 235-240.
Faculty members: Update your contact information and create a profile.